Name | 2-(1H-benzimidazol-2-ylsulfanyl)-N'-[(3-bromo-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]propanehydrazide |
---|---|
Synonyms |
Propanoic acid, 2-(1H-benzimidazol-2-ylthio)-, 2-[(1E)-(5-bromo-2-hydroxyphenyl)methylene]hydrazide
2-(1H-Benzimidazol-2-ylsulfanyl)-N'-[(E)-(5-bromo-2-hydroxyphenyl)methylene]propanehydrazide MNI-caged-L-glutamate KH7 (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N'-(5-bromo-2-hydroxybenzylidene)propanehydrazide |
Description | KH7 is a soluble adenylyl cyclase (sAC)-specific inhibitor, with IC50s of 3-10 μM toward both recombinant purified human sACt protein and heterologously expressed sACt in cellular assays[1]. |
---|---|
Related Catalog | |
Target |
IC50: 3-10 μM (recombinant sACt)[1]. |
References |
Density | 1.6±0.1 g/cm3 |
---|---|
Molecular Formula | C17H15BrN4O2S |
Molecular Weight | 419.296 |
Exact Mass | 418.009888 |
PSA | 115.67000 |
LogP | 6.01 |
Index of Refraction | 1.716 |
Storage condition | 2-8℃ |
Symbol |
GHS06 |
---|---|
Signal Word | Danger |
Hazard Statements | H301 |
Precautionary Statements | P301 + P310 |
RIDADR | UN 2811 6.1 / PGIII |